Title:
HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/207241
Kind Code:
A1
Abstract:
The present invention relates to a halogen-substituted isoindoline compound represented by formula I below and use thereof. The compound of the present invention has significantly better anti-tumor activity, and can be prepared into an oral dosage form which is more convenient, safe, and economical. Therefore, the utilization value of the compound is remarkably improved compared with that of an existing compound.
Inventors:
HU WEI (CN)
WANG LIQIANG (CN)
CAI XIN (CN)
WANG LIQIANG (CN)
CAI XIN (CN)
Application Number:
PCT/CN2023/074286
Publication Date:
November 02, 2023
Filing Date:
February 02, 2023
Export Citation:
Assignee:
CHENGDU FENDI PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/454; C07D401/04; A61K31/4545; A61P35/00; A61P35/02; C07D401/14; C07D405/14; C07D409/14; C07D417/14
Domestic Patent References:
| WO2022029138A1 | 2022-02-10 | |||
| WO2020118098A1 | 2020-06-11 | |||
| WO2023274246A1 | 2023-01-05 | |||
| WO2020242960A1 | 2020-12-03 | |||
| WO2019241274A1 | 2019-12-19 |
Foreign References:
| CN114835680A | 2022-08-02 | |||
| US20180264000A1 | 2018-09-20 | |||
| CN102112463A | 2011-06-29 |
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM et al. (CN)
Download PDF: